Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Feb 12, 2022 10:50am
158 Views
Post# 34423120

RE:RE:RE:Cost control

RE:RE:RE:Cost control

The presentation and the quarterly filings are the accurate count, not LinkedIn numbers, as you say. I recall thinking it's grown a tad on a Y-o-Y basis so they likely lost or replaced some of those people given the new hiring. While there's a load of ex-big pharma sales people available on the labor supply side, good ones always want the biggest franchise and one that's growing.  Probably those who thought Trogarzo would be 3-4x the size it is have already bailed as that became clear the first 24 months on the market.  

A leading edge target-based oncology drug in 4 or more indications would completely change the attractiveness of being a THTX salesperson. You could probably get some top hires in the big cancer center cities. 


palinc2000 wrote: The Corporate Presentation  mentions 165 employees 

 

palinc2000 wrote: 62 employees  in Montreal and 113 in total...
Where can we see the deletions?




<< Previous
Bullboard Posts
Next >>